INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Grant or awardVerified data

Stone Benjamin reported TRAX

Chief Business Officer · First Tracks Biotherapeutics, Inc. · First Tracks Biotherapeutics, Inc. — Performance Stock Units

Side
A
Value
—
Shares
60.5K
Price
—
Executed
Aug 15, 2026
Disclosed
Aug 18, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Aug 15 executedAug 18, 2026 disclosed

TRAX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
21/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+13 / 25

No reported dollar value · 78.4% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · TRAX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    SB
    Stone BenjaminChief Business Officer
    TRAXFirst Tracks Biotherapeutics, Inc.
    Grant or award
    		A—
    42.5K sh
    		Nov 1, 2026Nov 3, 2026
    traded Nov 1, 2026
    		+2dSEC FORM 4

    Evidence

    9
    WA
    Ware J. AnthonyDirector
    TRAXFirst Tracks Biotherapeutics, Inc.
    Option exercise
    		M—
    10.7K sh
    		Sep 2, 2026Sep 4, 2026
    traded Sep 2, 2026
    		+2dSEC FORM 4

    Evidence

    24
    WA
    Ware J. AnthonyDirector
    TRAXFirst Tracks Biotherapeutics, Inc.
    Option exercise
    		M$225K
    39.3K sh
    		Sep 2, 2026Sep 4, 2026
    traded Sep 2, 2026
    		+2dSEC FORM 4

    Evidence

    42
    WA
    Ware J. AnthonyDirector
    TRAXFirst Tracks Biotherapeutics, Inc.
    Open-market sale
    		SELL$1.76M
    39.3K sh
    		Sep 2, 2026Sep 4, 2026
    traded Sep 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    WA
    Ware J. AnthonyDirector
    TRAXFirst Tracks Biotherapeutics, Inc.
    Option exercise
    		M—
    28.6K sh
    		Sep 2, 2026Sep 4, 2026
    traded Sep 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SB
    Stone BenjaminChief Business Officer
    TRAXFirst Tracks Biotherapeutics, Inc.
    Grant or award
    		A—
    26.7K sh
    		May 12, 2026May 14, 2026
    traded May 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SB
    Stone BenjaminChief Business Officer
    TRAXFirst Tracks Biotherapeutics, Inc.
    Grant or award
    		A—
    72.3K sh
    		May 12, 2026May 14, 2026
    traded May 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    TA
    Tamboli AjimChief Financial Officer
    TRAXFirst Tracks Biotherapeutics, Inc.
    Grant or award
    		A—
    5,000 sh
    		May 12, 2026May 14, 2026
    traded May 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    TA
    Tamboli AjimChief Financial Officer
    TRAXFirst Tracks Biotherapeutics, Inc.
    Grant or award
    		A—
    13.6K sh
    		May 12, 2026May 14, 2026
    traded May 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    TA
    Tamboli AjimChief Financial Officer
    TRAXFirst Tracks Biotherapeutics, Inc.
    Grant or award
    		A—
    41.2K sh
    		Apr 22, 2026Apr 23, 2026
    traded Apr 22, 2026
    		+1dSEC FORM 4

    Evidence

    9
    TA
    Tamboli AjimChief Financial Officer
    TRAXFirst Tracks Biotherapeutics, Inc.
    Grant or award
    		A—
    41.2K sh
    		Apr 21, 2026Apr 23, 2026
    traded Apr 21, 2026
    		+2dSEC FORM 4

    Evidence

    9
    TA
    Tamboli AjimChief Financial Officer
    TRAXFirst Tracks Biotherapeutics, Inc.
    Grant or award
    		A—
    41.2K sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    TA
    Tamboli AjimChief Financial Officer
    TRAXFirst Tracks Biotherapeutics, Inc.
    Grant or award
    		A—
    45.7K sh
    		Apr 21, 2026Apr 23, 2026
    traded Apr 21, 2026
    		+2dSEC FORM 4

    Evidence

    9
    WA
    Ware J. AnthonyDirector
    TRAXFirst Tracks Biotherapeutics, Inc.
    Grant or award
    		A—
    4,000 sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    9
    LF
    Lizzul Paul F.Chief Medical Officer
    TRAXFirst Tracks Biotherapeutics, Inc.
    Grant or award
    		A—
    83.5K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    9
    LF
    Lizzul Paul F.Chief Medical Officer
    TRAXFirst Tracks Biotherapeutics, Inc.
    Grant or award
    		A—
    45.0K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    9
    LF
    Lizzul Paul F.Chief Medical Officer
    TRAXFirst Tracks Biotherapeutics, Inc.
    Grant or award
    		A—
    70.0K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    9
    LF
    Lizzul Paul F.Chief Medical Officer
    TRAXFirst Tracks Biotherapeutics, Inc.
    Grant or award
    		A—
    67.1K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    9
    LF
    Lizzul Paul F.Chief Medical Officer
    TRAXFirst Tracks Biotherapeutics, Inc.
    Grant or award
    		A—
    115.5K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    9
    LF
    Lizzul Paul F.Chief Medical Officer
    TRAXFirst Tracks Biotherapeutics, Inc.
    Grant or award
    		A—
    97.2K sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002128786-26-000006
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Aug 15, 2026
    Published
    Aug 18, 2026
    Ingested by INSIDER
    Nov 5, 02:22 UTC
    Last re-read
    Nov 5, 02:22 UTC

    Extracted facts

    Filer
    Stone Benjamin
    Role
    Chief Business Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    First Tracks Biotherapeutics, Inc. — Performance Stock Units
    Ticker
    TRAX
    Shares
    60.5K
    Price per share
    $0
    Execution date (reported)
    Aug 15, 2026
    Owned after transaction
    137.7K shares
    Days from execution to publication
    3

    What this establishes

    Stone Benjamin filed this Form 4 reporting a grant or award of TRAX on Aug 15, 2026. It became public on Aug 18, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Business Officer
    Stone Benjamincik:0002128786
    Issuer
    First Tracks Biotherapeutics, Inc.cik:0002091349

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.